New Immunotherapy drug outperforms chemotherapy for a form of lung cancer

clinical trials for cancer

CHICAGO — A new drug that unleashes the body’s immune system on cancer cells performed better than a traditional chemotherapy agent in fighting an advanced form of lung cancer, researchers reported Friday. The new drug was also less toxic to patients.

Nivolumab, one of three government-approved drugs that stimulate the immune system to take on foreign invaders, improved outcomes for 19.2 percent of patients with non-squamous cell non-small cell lung cancer, compared with 12.4 percent of people who were treated with docetaxel. Patients also survived longer — a median of 12.2 months vs. 9.4 months for those on chemotherapy, and saw a 27 percent smaller chance of death while read more

2 Comments on "New Immunotherapy drug outperforms chemotherapy for a form of lung cancer"

  1. Helpful post. I’ll come back here for even more.

    Very good site.

  2. I think this is among the most vital info for me. And I
    am glad reading your article. Nevertheless want
    to remark on some general things, The site style is
    great, the articles are actually great : D. Good job, cheers.

Comments are closed.

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.